Pfizer inks marketing deal for colorectal cancer test; Zai Lab douses a hot rumor about a Hong Kong IPO

→ Pfizer has inked a deal with Madison, WI-based Exact Sciences to help promote a DNA screening test for colorectal cancer. The agreement, which extends to 2021, has the two companies sharing marketing and promotion expenses for the test. Pfizer will join Exact’s sales efforts, reaching out to physicians and health systems to promote the test called Cologuard. Pfizer, of course, will get a cut of the gross profits.

Zai Lab $ZLAB is reportedly following BeiGene’s footsteps to take a shot at a secondary listing in Hong Kong. Unnamed sources told Reuters that the Chinese biotech unicorn — and Nasdaq darling, raising $172 million in its IPO last year — is in talks with advisers to float as much as 20% of its enlarged share base on the stock exchange. Officials at the company, however, tell Endpoints News that the rumors are not true, and that no HKEX IPO is in the offing.

→ Gaithersburg, MD-based Sensei Biotherapeutics has named Ildiko Csiki as its chief medical officer. Csiki most recently worked as vice president of immuno-oncology clinical development at Inovio Pharmaceuticals. Earlier she worked as clinical development lead for Merck‘s Keytruda program.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->